Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

Not Applicable

Not yet recruiting

• Conditions: Primary Cutaneous Amyloidosis
• Interventions: Biological: Stapokibart; Other: Placebo drug

• Registration Number: NCT07143864
• Lead Sponsor: First Affiliated Hospital of Chongqing Medical University

Brief Summary

This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-13
• Study First Submitted QC: 2025-08-23
• Last Update Submitted: 2025-08-23
• Study First Posted: 2025-08-27
• Last Update Posted: 2025-08-27
• Study Start: 2025-09-15
• Primary Completion: 2026-12-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Males or females aged 18 to 75 years, with a diagnosis of PCA confirmed by skin biopsy, and an IGA score of ≥3, a AASI score of ≥5, and a BSA involvement of ≥5%.
2. Subjects who have received at least 4 weeks of mid-to-high potency or at least 2 weeks of very high potency topical corticosteroids (TCS) or an adequate course of systemic corticosteroids within the 6 months prior to screening, but with an inadequate response; or subjects who are unable to receive the above treatments due to adverse reactions or potential risks.
3. Prior to the first dose, subjects must have used a moisturizer continuously for at least 1 week, once daily, and must continue to use it throughout the study period.
4. Able to understand and complete study-related questionnaires.
5. Able to read, understand, and are willing to sign the informed consent form.
6. Willing and able to comply with study visits and related procedures.
7. Women of childbearing potential must agree to use contraception (such as intrauterine devices, oral contraceptives, or condoms) during the study and for 6 months after the study ends; must have a negative serum pregnancy test within 7 days before the first dose and must not be breastfeeding; male subjects must agree to use contraception during the study and for 6 months after the study ends.

Exclusion Criteria

1. Use of any of the following treatments within 4 weeks prior to randomization: a. Immunosuppressants or immunomodulators, such as systemic corticosteroids, cyclosporine, mycophenolate mofetil, interferon gamma (IFN-γ), azathioprine, methotrexate, and Janus kinase (JAK) inhibitors; b. UV phototherapy; c. Systemic traditional Chinese medicine (TCM) treatment.
2. Use of topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), TCM, or phosphodiesterase 4 (PDE-4) inhibitors within 2 weeks prior to randomization.
3. Receipt of anti-IL-4R monoclonal antibodies, anti-IgE monoclonal antibodies, or other biologics within 12 weeks or 5 half-lives (whichever is longer) prior to randomization.
4. Receipt of live attenuated vaccines within 12 weeks prior to randomization or planned vaccination during the study period.
5. Use of antihistamines within 1 week prior to randomization (subjects who have been on a stable dose of antihistamines for at least 7 days prior to randomization and plan to continue during the study period may be included).
6. Receipt of allergen-specific immunotherapy (desensitization therapy) within 6 months prior to randomization.
7. Presence of any skin comorbidities that may interfere with study assessments, including but not limited to scabies, cutaneous T-cell lymphoma, psoriasis, etc.
8. Previous receipt of at least 12 consecutive doses of anti-IL-4Rα or IL-13 monoclonal antibodies with inadequate clinical response (defined as failure to achieve AASI 50 during treatment).
9. Presence of any other significant medical history that the investigator deems would pose a risk to the subject's safety or be poorly controlled if the subject participates in the study, in addition to PCA.
10. History of known or suspected immunosuppression (immunodeficiency), including a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis), even if the infection has resolved; or unusual frequency, recurrence, or chronicity of infections (at the investigator's discretion).
11. Subjects with any type of active malignancy or a history of malignancy (except for cervical cancer that has been cured for more than 5 years prior to the screening period, or non-metastatic squamous cell carcinoma of the skin, basal cell carcinoma, and papillary thyroid cancer).
12. Presence of active Mycobacterium tuberculosis infection.
13. Subjects with severe liver or kidney function impairment during the screening period, such as aspartate aminotransferase or alanine aminotransferase >2 times the upper limit of normal (ULN), total bilirubin >1.5 times ULN, serum creatinine >1.2 times ULN, etc.
14. Presence of active hepatitis during the screening period, or positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and HBV-DNA, or positive for hepatitis C virus (HCV) antibody and HCV-RNA.
15. Positive for HIV antibody during the screening period, or history of HIV infection.
16. Positive for Treponema pallidum antibody during the screening period (subjects who have undergone standard treatment and have a negative non-treponemal antigen serological test may participate in the study).
17. Participation in another clinical trial of a drug or medical device within 12 weeks prior to randomization.
18. Presence of chronic active or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to randomization. After resolution of the infection, the subject may be re-screened once.
19. Subjects who plan to undergo major surgical procedures during the study period.
20. Pregnant or breastfeeding women.
21. Subjects with a history of alcoholism, drug abuse, or known drug dependence.
22. History of atopic keratoconjunctivitis involving the cornea.
23. Any medical or psychiatric conditions that the investigator deems would pose a risk to the subject, interfere with participation in the study, or confound the interpretation of study results.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Stapokibart	Stapokibart	-
Placebo	Placebo drug	-

Primary Outcome Measures

Name	Time	Method
The percentage of subjects achieving AASI-75 at Week 16 of treatment	At the end of treatment at 16 weeks	AASI: Amyloidosis Area and Severity Index. The minimum and maximum values: 0-72. Higher scores mean more serious situations.; AASI-75: A 75% or greater improvement from baseline in the AASI. The minimum and maximum values: 0%-100%. Higher scores mean a better outcome.

Secondary Outcome Measures

Name	Time	Method
The percentage of subjects with a weekly average reduction of≥4 points in PP-NRS score at Week 16 of treatment compared to baseline	At the end of treatment at 16 weeks	PP-NRS: Peak Pruritus Numerical Rating Scale. The minimum and maximum values: 0-10. Higher scores mean more serious situations.
The percentage of subjects with an IGA score of 0 or 1 and a reduction of≥2 points compared to baseline.	At the end of treatment at 16 weeks	IGA: Investigator Global Assessment. The minimum and maximum values: 0-4. Higher scores mean more serious situations.
The percentage of subjects achieving AASI-50 compared to baseline.	At the end of treatment at 16 weeks	AASI: Amyloidosis Area and Severity Index. The minimum and maximum values: 0-72. Higher scores mean more serious situations.; AASI-50: A 50% or greater improvement from baseline in the AASI. The minimum and maximum values: 0%-100%. Higher scores mean a better outcome.
The percentage of subjects with a weekly average reduction of≥3 points in PP-NRS score compared to baseline	At the end of treatment at 16 weeks	PP-NRS: Peak Pruritus Numerical Rating Scale. The minimum and maximum values: 0-10. Higher scores mean more serious situations.
Change rates in BSA involvement compared to baseline.	At the end of treatment at 16 weeks	BSA: Body Surface Area. The minimum and maximum values: 0-100%. Higher scores mean more serious situations.
Changes in DLQI scores compared to baseline.	At the end of treatment at 16 weeks	DLQI: Dermatology Life Quality Index. The minimum and maximum values: 0-30. Higher scores mean more serious situations.
Changes in absolute eosinophil counts in complete blood counts compared to baseline.	At the end of treatment at 16 weeks
Changes in IgE levels in complete blood counts compared to baseline.	At the end of treatment at 16 weeks
Changes in histopathology of skin lesions compared to baseline in some subjects	At the end of follow-up at 28 weeks